The bill requires the Executive Office of Health and Human Services to submit a quarterly report detailing the projected total costs for pharmaceutical pipeline drugs anticipated to be available for utilization within the next fiscal year. Specifically, it focuses on drugs identified by the executive office that are expected to enter the market between October 1, 2025, and September 30, 2026. The report indicates that 50 pipeline market entries have been identified, with an estimated expenditure of approximately $20 million for MassHealth members, which includes those enrolled in managed care. This marks a slight increase from a previous estimate of $19.9 million based on 67 pipeline entries.

Additionally, the report highlights that high-cost cell and gene therapies are significant contributors to the overall spending. The bill emphasizes the importance of tracking these costs to ensure proper budgeting and resource allocation within the state's healthcare system. For any inquiries regarding the report, contact information for Sarah Nordberg-Dunlea is provided, including her email address, which has been newly inserted into the legal language.